Literature DB >> 24532201

Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008-2012.

E H Martínez-Lapiscina1, E Fraga-Pumar, X Pastor, M Gómez, A Conesa, R Lozano-Rubí, B Sánchez-Dalmau, A Alonso, Pablo Villoslada.   

Abstract

It is currently believed that the incidence rate of optic neuritis (ON) ranges between 0.56 and 5.1 cases per 100,000 person-years. However, since these figures were generated, they have not been updated and there are suggestions that the incidence of ON is on the rise. When designing new therapies and clinical trials for ON, and to improve the management this disease, it is important to have accurate epidemiological data. Thus, we set out to obtain the prevalence and incidence rates of ON in Barcelona (Spain) from 2008 to 2012, by a retrospective evaluation of electronic hospital records at the Hospital Clinic of Barcelona (population of 300,000 in the catchment area) matching the following ICD-9-CM codes as search terms: 377.3-optic neuritis; 377.30-optic neuritis, unspecific; 377.31-optic papillitis; 377.32-retrobulbar neuritis, acute; 377.39-other optic neuritis and "optic neuropathy". Demographic and clinical data were collected from records with a confirmed diagnosis of ON, including cases of idiopathic ON, multiple sclerosis, neuromyelitis optica and CRION. The prevalence of acute ON on 31 December 2012 was 2.75 cases per 100,000 people. The mean annual prevalence of acute ON during the 2008-2012 period was 7.87 cases per 100,000 person-year and the mean annual incidence rate was 5.36 cases per 100,000 person-years. The incidence of ON in Barcelona during 2008-2012 was higher than previously reported. This increase may reflect the evolution of diagnostic criteria, the use of a referral-center approach instead of a population-based approach, increased awareness of demyelinating diseases, latitude-related factors and possibly a true increase in its incidence.

Entities:  

Mesh:

Year:  2014        PMID: 24532201     DOI: 10.1007/s00415-014-7266-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  33 in total

1.  Epidemiology of monosymptomatic optic neuritis in Rijeka County, Croatia: meteorological aspects.

Authors:  Karmen Loncarek; Ines Brajac; Igor Petricek; Hrvoje Stalekar; Branimir Cerovski; Rajko Pokupe
Journal:  Coll Antropol       Date:  2005-06

2.  Latitudinal variation in incidence and type of first central nervous system demyelinating events.

Authors:  Bruce V Taylor; Robyn M Lucas; Keith Dear; Trevor J Kilpatrick; Michael P Pender; Ingrid A F van der Mei; Caron Chapman; Alan Coulthard; Terence Dwyer; Anthony J McMichael; Patricia C Valery; David Williams; Anne-Louise Ponsonby
Journal:  Mult Scler       Date:  2010-02-18       Impact factor: 6.312

3.  Optic neuritis in the two northernmost counties of Norway. A study of incidence and the prospect of later development of multiple sclerosis.

Authors:  M Grønning; S I Mellgren; K Schive
Journal:  Arctic Med Res       Date:  1989-07

4.  Optic neuritis in Orientals and Caucasians.

Authors:  M Alter; J Good; M Okihiro
Journal:  Neurology       Date:  1973-06       Impact factor: 9.910

5.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

6.  The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1991-12

7.  Optic neuritis among National Health Insurance enrollees in Taiwan, 2000-2004.

Authors:  Lin-Chung Woung; Ching-Heng Lin; Ching-Yao Tsai; Ming-Tsu Tsai; Jieh-Ren Jou; Pesus Chou
Journal:  Neuroepidemiology       Date:  2008-01-07       Impact factor: 3.282

8.  A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.

Authors:  R W Beck; P A Cleary; M M Anderson; J L Keltner; W T Shults; D I Kaufman; E G Buckley; J J Corbett; M J Kupersmith; N R Miller
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial.

Authors: 
Journal:  Ophthalmology       Date:  2007-11-05       Impact factor: 12.079

View more
  9 in total

1.  Visual field impairment captures disease burden in multiple sclerosis.

Authors:  Santiago Ortiz-Perez; Magí Andorra; Bernardo Sanchez-Dalmau; Rubén Torres-Torres; David Calbet; Erika J Lampert; Salut Alba-Arbalat; Ana M Guerrero-Zamora; Irati Zubizarreta; Nuria Sola-Valls; Sara Llufriu; María Sepúlveda; Albert Saiz; Pablo Villoslada; Elena H Martinez-Lapiscina
Journal:  J Neurol       Date:  2016-02-09       Impact factor: 4.849

Review 2.  Update on Optic Neuritis: An International View.

Authors:  Simon J Hickman; Axel Petzold
Journal:  Neuroophthalmology       Date:  2021-08-31

3.  Recurrent isolated optic neuritis: A study on 22 patients.

Authors:  Mahsa Arzani; Mohammad Ali Sahraian; Hamed Rezaei; Abdorreza Naser Moghadasi
Journal:  Iran J Neurol       Date:  2017-07-06

Review 4.  Vision and vision-related outcome measures in multiple sclerosis.

Authors:  Laura J Balcer; David H Miller; Stephen C Reingold; Jeffrey A Cohen
Journal:  Brain       Date:  2014-11-28       Impact factor: 13.501

Review 5.  Melatonin as a Therapeutic Resource for Inflammatory Visual Diseases.

Authors:  Marcos L Aranda; María Florencia González Fleitas; Hernán Dieguez; Agustina Iaquinandi; Pablo H Sande; Damián Dorfman; Ruth E Rosenstein
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

6.  Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project.

Authors:  Corinne Willame; Caitlin Dodd; Lieke van der Aa; Gino Picelli; Hanne-Dorthe Emborg; Johnny Kahlert; Rosa Gini; Consuelo Huerta; Elisa Martín-Merino; Chris McGee; Simon de Lusignan; Giuseppe Roberto; Marco Villa; Daniel Weibel; Lina Titievsky; Miriam C J M Sturkenboom
Journal:  Drug Saf       Date:  2021-01-19       Impact factor: 5.606

7.  Neurological autoimmune diseases following vaccinations against SARS-CoV-2: a case series.

Authors:  Leon D Kaulen; Sofia Doubrovinskaia; Christoph Mooshage; Berit Jordan; Jan Purrucker; Carmen Haubner; Corinna Seliger; Hanns-Martin Lorenz; Simon Nagel; Brigitte Wildemann; Martin Bendszus; Wolfgang Wick; Silvia Schönenberger
Journal:  Eur J Neurol       Date:  2021-10-31       Impact factor: 6.288

Review 8.  Emerging concepts in the treatment of optic neuritis: mesenchymal stem cell-derived extracellular vesicles.

Authors:  Anagha Aneesh; Alice Liu; Biji Mathew; Steven Roth; Heather E Moss; Douglas Feinstein; Sriram Ravindran
Journal:  Stem Cell Res Ther       Date:  2021-12-04       Impact factor: 8.079

Review 9.  The changing landscape of optic neuritis: a narrative review.

Authors:  Lindsey B De Lott; Jeffrey L Bennett; Fiona Costello
Journal:  J Neurol       Date:  2021-01-03       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.